When putting together your watch list, look for stocks with an 80 or higher RS Rating. PTC Therapeutics just met that criteria with a new score of 84.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the top-performing stocks often have an RS Rating of at least 80 in the early stages of their moves.
PTC Therapeutics broke out earlier, but has fallen back below the prior 50.60 entry from a double bottom. In the scenario where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new pattern to take shape. Also keep in mind that the latest pattern is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one.
The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 460%.
PTC Therapeutics earns the No. 40 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
